MA53130A - Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) - Google Patents
Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada)Info
- Publication number
- MA53130A MA53130A MA053130A MA53130A MA53130A MA 53130 A MA53130 A MA 53130A MA 053130 A MA053130 A MA 053130A MA 53130 A MA53130 A MA 53130A MA 53130 A MA53130 A MA 53130A
- Authority
- MA
- Morocco
- Prior art keywords
- drug
- ada
- interference mitigation
- immunological assay
- mitigation methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696016P | 2018-07-10 | 2018-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53130A true MA53130A (fr) | 2021-05-19 |
Family
ID=67544324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053130A MA53130A (fr) | 2018-07-10 | 2019-07-09 | Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12055551B2 (https=) |
| EP (1) | EP3821255B1 (https=) |
| JP (3) | JP7493459B2 (https=) |
| KR (1) | KR102754704B1 (https=) |
| CN (1) | CN112384808B (https=) |
| AU (1) | AU2019301614B2 (https=) |
| BR (1) | BR112020022912A2 (https=) |
| EA (1) | EA202190237A1 (https=) |
| ES (1) | ES2993989T3 (https=) |
| IL (1) | IL277888B2 (https=) |
| MA (1) | MA53130A (https=) |
| MX (1) | MX2021000331A (https=) |
| MY (1) | MY207418A (https=) |
| SG (1) | SG11202011283TA (https=) |
| WO (1) | WO2020014194A1 (https=) |
| ZA (1) | ZA202006409B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
| CN114264814B (zh) * | 2021-12-30 | 2025-03-14 | 苏州和锐生物科技有限公司 | 一种pd-1生物制剂的抗体检测试剂盒及制备方法 |
| CN114324894A (zh) * | 2021-12-31 | 2022-04-12 | 军科正源（北京）药物研究有限责任公司 | 一种检测贝伐珠单抗抗药性抗体的新型分析方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| JP2025514738A (ja) * | 2022-04-19 | 2025-05-09 | ソングァン メディカル ファンデーション | 血液中の抗薬物抗体濃度測定による生物学的薬物に対する治療反応性の予測方法 |
| WO2024044622A1 (en) * | 2022-08-24 | 2024-02-29 | Amgen Inc. | Anti-drug antibody assays |
| CN115586337A (zh) * | 2022-09-14 | 2023-01-10 | 杭州赛基生物科技有限公司 | 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法 |
| CN120239821A (zh) * | 2022-09-23 | 2025-07-01 | 默沙东有限责任公司 | 中和抗体测定方法 |
| CN115575468B (zh) * | 2022-09-30 | 2025-08-26 | 华润生物医药有限公司 | 一种检测抗重组人GLP-1-Fc融合蛋白抗体的方法 |
| CN115856322A (zh) * | 2022-12-23 | 2023-03-28 | 同昕生物技术（北京）有限公司 | 用于抗奥马株单抗药物抗体检测的试剂及其应用 |
| CN117805382B (zh) * | 2024-02-28 | 2024-05-03 | 军科正源（北京）药物研究有限责任公司 | 检测抗利妥昔单抗中和抗体的方法 |
| WO2025224166A1 (en) * | 2024-04-23 | 2025-10-30 | F. Hoffmann-La Roche Ag | Anti-drug antibody assays |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856469A (en) | 1973-01-02 | 1974-12-24 | Syva Corp | Interferant removal from amphetamine immunoassay |
| JPS55145690A (en) | 1979-05-04 | 1980-11-13 | Toyama Chem Co Ltd | Novel penicillin and cephalosporin, and its salt |
| JPS6454356A (en) * | 1987-08-26 | 1989-03-01 | Meidensha Electric Mfg Co Ltd | Method for suppressing non-specific adsorption of antibody to solid phase antigen |
| JPH02138872A (ja) * | 1988-11-18 | 1990-05-28 | Asahi Chem Ind Co Ltd | 癌関連物質のための免疫測定方法 |
| US20060281132A1 (en) * | 2003-09-26 | 2006-12-14 | Fumihisa Kitawaki | Method of immunoreaction measurement and, for use therein, reagent, kit and optical cell |
| CN101680880A (zh) | 2007-05-07 | 2010-03-24 | 惠氏公司 | 免疫检定中由抗碳水化合物抗体引起的干扰的消除 |
| WO2009022001A1 (en) | 2007-08-16 | 2009-02-19 | Novartis Ag | Improvement of drug tolerance in immunogenicity testing |
| DK2723769T4 (da) * | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| CN105378480B (zh) * | 2013-07-04 | 2018-06-12 | 豪夫迈·罗氏有限公司 | 检测血清样品中抗药物抗体的干扰抑制性免疫测定 |
| CA2939080A1 (en) * | 2014-02-11 | 2015-08-20 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| WO2017096262A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| US20190145985A1 (en) | 2017-11-10 | 2019-05-16 | BioAgilytix Labs, LLC | Method for eliminating target interference |
| AU2018374469B2 (en) | 2017-11-29 | 2022-06-16 | F. Hoffmann-La Roche Ag | Target interference suppressed anti-drug antibody assay |
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
-
2019
- 2019-07-09 SG SG11202011283TA patent/SG11202011283TA/en unknown
- 2019-07-09 WO PCT/US2019/040950 patent/WO2020014194A1/en not_active Ceased
- 2019-07-09 KR KR1020207033049A patent/KR102754704B1/ko active Active
- 2019-07-09 IL IL277888A patent/IL277888B2/en unknown
- 2019-07-09 MY MYPI2020005155A patent/MY207418A/en unknown
- 2019-07-09 CN CN201980046236.XA patent/CN112384808B/zh active Active
- 2019-07-09 MX MX2021000331A patent/MX2021000331A/es unknown
- 2019-07-09 JP JP2020564556A patent/JP7493459B2/ja active Active
- 2019-07-09 MA MA053130A patent/MA53130A/fr unknown
- 2019-07-09 EP EP19749872.8A patent/EP3821255B1/en active Active
- 2019-07-09 EA EA202190237A patent/EA202190237A1/ru unknown
- 2019-07-09 BR BR112020022912-1A patent/BR112020022912A2/pt unknown
- 2019-07-09 US US16/506,379 patent/US12055551B2/en active Active
- 2019-07-09 ES ES19749872T patent/ES2993989T3/es active Active
- 2019-07-09 AU AU2019301614A patent/AU2019301614B2/en active Active
-
2020
- 2020-10-15 ZA ZA2020/06409A patent/ZA202006409B/en unknown
-
2024
- 2024-02-20 JP JP2024023599A patent/JP2024045646A/ja active Pending
- 2024-07-03 US US18/763,265 patent/US20240353423A1/en active Pending
-
2025
- 2025-10-23 JP JP2025179025A patent/JP2026012856A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112384808A (zh) | 2021-02-19 |
| IL277888B1 (en) | 2024-12-01 |
| MY207418A (en) | 2025-02-26 |
| US20240353423A1 (en) | 2024-10-24 |
| ZA202006409B (en) | 2025-07-30 |
| KR20210031854A (ko) | 2021-03-23 |
| AU2019301614B2 (en) | 2025-11-20 |
| JP2026012856A (ja) | 2026-01-27 |
| JP2024045646A (ja) | 2024-04-02 |
| EP3821255B1 (en) | 2024-08-28 |
| BR112020022912A2 (pt) | 2021-02-23 |
| KR102754704B1 (ko) | 2025-01-20 |
| JP7493459B2 (ja) | 2024-05-31 |
| US12055551B2 (en) | 2024-08-06 |
| WO2020014194A1 (en) | 2020-01-16 |
| IL277888B2 (en) | 2025-04-01 |
| IL277888A (en) | 2020-11-30 |
| CN112384808B (zh) | 2024-10-11 |
| ES2993989T3 (en) | 2025-01-15 |
| MX2021000331A (es) | 2021-03-25 |
| EP3821255A1 (en) | 2021-05-19 |
| CA3098206A1 (en) | 2020-01-16 |
| AU2019301614A1 (en) | 2020-10-22 |
| US20200018770A1 (en) | 2020-01-16 |
| JP2021531448A (ja) | 2021-11-18 |
| SG11202011283TA (en) | 2020-12-30 |
| EA202190237A1 (ru) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53130A (fr) | Procédés d'atténuation d'interférence de cible médicamenteuse dans un dosage immunologique d'anticorps anti-médicament (ada) | |
| EP4025908A4 (en) | ANTI-DRUG ANTIBODY TEST | |
| EP3797123A4 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| EP3824096A4 (en) | NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF | |
| EP3665187A4 (en) | TEST PROCEDURES FOR IMPROVED ANALYTE DETECTION | |
| EP3515490A4 (en) | ANTIBODIES AGAINST SIGNAL REGULATORY PROTEIN ALPHA AND METHOD FOR USE | |
| MA53015A (fr) | Anticorps anti-sirp-bêta1 et procédés d'utilisation associés | |
| MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| EP3436037A4 (en) | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA52416A (fr) | Anticorps b7-h4 et leurs procédés d'utilisation | |
| IL262514A (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| EP3877418A4 (en) | DOSING REGIME OF AN ANTI-TIGIT ANTIBODY FOR THE TREATMENT OF CANCER | |
| EP3645049A4 (en) | MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF | |
| EP3873941A4 (en) | ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF | |
| EP3873939A4 (en) | ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | |
| EP3733705A4 (en) | MONOCLONAL ANTIBODIES AND METHOD OF USING THEM | |
| EP3626266A4 (en) | CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF | |
| MA54052A (fr) | Formulation d'anticorps | |
| EP3927729A4 (en) | Therapeutic antibody formulation | |
| MA51207A (fr) | Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation | |
| EP3645740A4 (en) | ANTI-PD-1 ANTIBODIES AND METHOD OF MANUFACTURING AND USE | |
| EP3977112A4 (en) | Mass spectrometry assay methods for detection of metabolites | |
| EP4061847A4 (en) | Anti-b7-h3 monoclonal antibody and methods of use thereof | |
| MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 |